IceCure Medical Ltd ICCM
Set alert
0.87 USD -0.06 -6.28%
At close · Oct 30
0.94 +0.07 +7.92%
After hours · Oct 30, 7:27 PM ET
0.8201 Day range 0.951
0.8701 52-week range 21.90
- YTD
- -95.25%
- 1 year
- -95.92%
- Open
- 0.94
- Prev close
- 0.9284
- Mkt cap
- 4.04M
- Vol
- 50.26K
- Avg vol
- 145.59K
- EPS
- -6.84
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8201
- High
- 0.951
- Forward P/E
- -4.48
- Beta
- 2.63
- Short ratio
- 0.46
- Inst. own
- 0.40%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 20, 2024
- 50-d avg
- 0.74766
- 200-d avg
- 0.852735
- 1y target
- 3.37
2Y chart
Events in this range
- Nov 8, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 26, 2024Earnings: -0.08; estimate -0.07; surprise -14.29%
- Nov 27, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jun 4, 2026Split: 1 for 30
Signals (94)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| MACD: Sell Signal | Oct 6, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 17, 2026 | 1 month ago |
| RSI: Oversold | Sep 9, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 31, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 21, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 31, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 8, 2026 | 3 months ago |
| SMA: Bearish | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| RSI: Oversold | May 29, 2026 | 5 months ago |
| RSI: Oversold | May 7, 2026 | 5 months ago |
| RSI: Oversold | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 15, 2026 | 6 months ago |
| RSI: Oversold | Apr 10, 2026 | 6 months ago |
| RSI: Oversold | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 20, 2026 | 7 months ago |
| SMA: Bullish | Mar 19, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 11, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| SMA: Bullish | Mar 4, 2026 | 8 months ago |
| SMA: Bearish | Mar 3, 2026 | 8 months ago |
| SMA: Bullish | Mar 2, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 20, 2026 | 8 months ago |
| RSI: Oversold | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 23, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| SMA: Bullish | Jan 15, 2026 | 9 months ago |
| SMA: Bearish | Jan 12, 2026 | 9 months ago |
| SMA: Bullish | Jan 8, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 5, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 30, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 17, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 16, 2025 | 10 months ago |
| RSI: Oversold | Nov 20, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 11, 2025 | 11 months ago |
| RSI: Oversold | Oct 28, 2025 | 1 year ago |
| RSI: Oversold | Oct 17, 2025 | 1 year ago |
| RSI: Oversold | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 9, 2025 | 1 year ago |
| SMA: Bullish | Oct 6, 2025 | 1 year ago |
| SMA: Bearish | Oct 3, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 24, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 22, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 16, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 15, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 28, 2025 | 1 year ago |
| RSI: Overbought | Aug 28, 2025 | 1 year ago |
| SMA: Bullish | Aug 25, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 21, 2025 | 1 year ago |
| RSI: Oversold | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| SMA: Bearish | Jul 17, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 10, 2025 | 1 year ago |
| SMA: Bullish | Jul 3, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| MACD: Buy Signal | May 22, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| SMA: Bearish | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 29, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 22, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 21, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 16, 2025 | 1 year ago |
| SMA: Bearish | Mar 20, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 20, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 17, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 25, 2025 | 1 year ago |
| RSI: Overbought | Feb 18, 2025 | 1 year ago |
| RSI: Overbought | Feb 13, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| RSI: Overbought | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
| RSI: Overbought | Jan 2, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 31, 2024 | 1 year ago |
| RSI: Overbought | Dec 26, 2024 | 1 year ago |
| RSI: Overbought | Dec 13, 2024 | 1 year ago |
Key statistics
- Market cap
- 62.16M
- Enterprise value
- 28.55M
- Trailing P/E
- 0.00
- Forward P/E
- -4.48
- PEG ratio
- 0.00
- Price / sales
- 18.63
- Price / book
- 4.21
- EPS (TTM)
- -0.28
- Beta
- 2.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 3.34M
- Revenue growth
- 7.90%
- Free cash flow
- -6.62M
- Total cash
- 10.46M
- Total debt
- 520.00K
- Return on equity
- -94.22%
- Shares outstanding
- 55.50M
- Short % of float
- 0.98%
- 50-day average
- 0.74766
- 200-day average
- 0.852735
Analyst view
Consensus: none
Price target (mean) 3.37 +286.9% upside
Now 0.8701
- Target (low)
- 2.50
- Target (mean)
- 3.37
- Target (high)
- 4.60
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 20, 2024
Expected Aug 20, 2024. Consensus EPS estimate -0.07.
Financials — quick view
ICCM Revenue — quarterly 907.00K
ICCM Net income — quarterly -4.50M
ICCM EPS — quarterly -1.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.07 | -0.08 | -0.01 | -14.29% |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | — | — | — |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | -0.06 | +0.01 | +14.29% |
| May 28, 2024 | Mar 1, 2024 | -0.08 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IceCure Medical Ltd
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- icecure-medical.com
News
- IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer
- IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- IceCure Medical Announces Presentations, Posters And Physician Workshops On Its ProSense Breast Cancer Cryoablation At The European Society Of Breast Imaging Annual Scientific Meeting
- IceCure Medical Adds Legacy Health In Portland, Oregon, As New U.S. Clinical Site For Its Post-Marketing ChoICE Study Evaluating Prosense Cryoablation For Treatment Of Low-Risk Breast Cancer
Your note
Sign in to keep a note on ICCM — it syncs with the Stock Master app.